The U.S. FDA has officially declared that Novo Nordisk’s (NVO) popular diabetes and weight loss therapies, Ozempic and Wegovy, are no longer in ...

HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which ...

Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.

Leerink notes that the shortage of Novo Nordisk’s (NVO) semaglutide, marketed as Wegovy and Ozempic, has been resolved according to the FDA.

Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...

Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...

It may be early, but some blazing investments have already delivered wealth-altering gains in this young year.

Hims & Hers Health Inc. has been on a meteoric rise, with shares soaring over 145% this year and more than sixfold in the ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

The Hims brand has primed people to view both their everyday health and the natural-aging processes as problems that can be ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Read more ...